MVI 118

Drug Profile

MVI 118

Alternative Names: AR vaccine - Madison Vaccines; pTVG-AR

Latest Information Update: 21 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Madison Vaccines
  • Developer Madison Vaccines; National Cancer Institute (USA); University of Wisconsin-Madison
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Androgen receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 01 Jul 2015 Phase-I clinical trials in Prostate cancer (Metastatic disease) in USA (Parenteral)
  • 23 Jan 2014 MVI 118 is available for licensing as of 23 Jan 2014.
  • 13 Jan 2014 Madison Vaccines plans a phase I trial for Prostate cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top